56 results about "Interaction site" patented technology

The interior cabin of a vehicle is provided with a vehicular sound-processing system that comprises an interior rearview mirror assembly, the mirror assembly including a mirror housing and a reflective element. An accessory is located in the interior cabin. The interior rearview mirror assembly comprises a user-interaction site for a wireless communication system, the wireless communication system communicating with the accessory. The user-interaction site comprises at least one microphone for producing an audio output in response to detection of vocal input of a human speaker in the interior cabin with the vehicle cabin noise superimposed thereon. Preferably, the user-interaction site further comprises at least one manually operated control input. The restricted-range wireless communication system preferably comprises one of a radio frequency restricted-range wireless communication system and an infrared restricted-range wireless communication system. Signals indicative of the vocal input detected at the user-interaction site of the interior mirror assembly are wirelessly broadcast to the accessory located in the interior cabin of the vehicle.

A consumable order-assistance system is provided for computer peripheral devices. The system includes a personal computer, at least one computer peripheral device, and a user interaction site. The personal computer has a messaging system. The at least one computer peripheral device has a messaging system. The communication link signal couples the personal computer with a provider of a consumable for the computer peripheral device. The user interaction site is configured to receive a notification from the computer peripheral device via the messaging system of a need to order a consumable. The user interaction site is provided within one of: a single-connection environment as an end user interface; an unmanaged network environment as a workgroup administrator interface; and a server-based centralized network environment as a centralized system administrator interface. A method is also provided.

A recombinant DNA containing a sequence (1) coding for a polypeptide heterologous to a filamentous haemagglutinin of Bordetella (Fha) fused within the reading frame to a sequence (2) located upstream from the first sequence. Sequence (2) codes for at least part of the Fha precursor, which part comprises at least the N-terminal region of a truncated mature Fha protein, which contains the interaction site of Fha and heparin and the secretion domain. This Fha protein is under the control of a promoter recognized by the cell polymerases of B. pertussis and is inserted into a B. pertussis cell culture, is expressed in the culture and excreted into the cell culture medium. The invention uses both the abilities of Bordetella and particularly B. pertussis to secrete or surface expose the heterologous polypeptide fused to the Fha portion corresponding to sequence (2), which does not appear to produce extracellular proteases, and the ease with which filamentous haemagglutinins can be isolated from other Bordetella proteins.

A personal record system and method having distributed record generation and access and personally centralized record storage for generating, storing and accessing personal records and a personal record card for use therein. The record system includes a plurality of interaction sites interconnected through a record network wherein each interaction site includes a record card read/write device, a record storage subsystem for storing at least records, and a record transaction process connected with the record card read/write device and record storage system for reading records from a record card and writing records to a record card and with the record network for transmitting records to and receiving records from at least other interaction sites.

This disclosure relates to binding agents with specificity for programmed cell death 1 (PD-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e.g., human immunodeficiency virus (HIV)), cancer and/or autoimmunity. In addition, this disclosure identifies a novel binding patch (“P2”) on PD-1 that is linked with a previously unidentified functional activity of PD-1 that is distinct from the interaction site involved with either the PD-L1 or PD-L2 ligands. Furthermore, we demonstrate that antibodies that interact with this region of PD-1 are able to act as antagonists of PD-1 and that this antagonism is further enhanced with the addition of antibodies that act through the blockade of the PD-1/PD-L1/L2 interaction.

The invention discloses a protein function prediction model generation method, a protein function prediction model generation device, a protein function prediction method and a protein function prediction device. The protein function prediction model generation method comprises the following steps: obtaining an amino acid sequence characteristic matrix of a training protein; obtaining a first characteristic matrix based on the amino acid sequence characteristic matrix of the training protein, wherein the first characteristic matrix corresponds to an interaction site in an amino acid sequence of the training protein; training a pre-constructed initial model according to the first characteristic matrix and a data label corresponding to the first characteristic matrix to obtain a protein function prediction model, wherein the amino acid sequence characteristic matrix comprises deep layer characteristics of a training protein amino acid sequence. The method has the advantages that the ambiguity of the surface characteristics of the amino acid sequence is avoided. The functional characteristics of the training protein can be expressed more accurately. The interference of amino acid residues irrelevant to the protein interaction capability in the amino acid sequence on protein function prediction is eliminated, so that the prediction accuracy and precision are improved.

The present invention provides a bispecific binding molecule, wherein said molecule comprises or consists of at least two domains whereby one of said at least two domains specifically binds to/interacts with the human CD3 complex and said domain comprises an amino acid sequence of an antibody derived light chain, wherein said amino acid sequence is a particularly identified amino acid sequence comprising specific amino acid substitutions, and a second domain is or contains at least one further antigen-interaction-site and/or at least one further effector domain. The invention further provides nucleic acid molecules encoding the bispecific binding molecules of the invention, vectors comprising said nucleic acid molecules and host cells transformed or transfected with said vectors. Moreover, the invention concerns a method for the production of bispecific binding molecules of the invention and compositions comprising the bispecific binding molecules of the invention, the nucleic acid molecules of the invention or the host cells of the invention.

The invention discloses a method for producing a nano-MV-MOF-based fluorescent enhanced test paper for biomarker detection. The method comprises the following steps: preparing a suspension from a nano-molecular tweezer-metal organic framework material and a metal ion coordination bonding material, uniformly coating a chromatography paper with the suspension, and drying the coated chromatography paper to obtain the test paper. The nano-MV-MOF material used in the test paper has an ultrahigh specific surface, uniformly-distributed host-guest interaction sites and a well-regulated host-guest interaction hole chemical environment, has excellent detection performances and can be repeatedly used. The test paper has the advantages of simplicity in production, easiness in implementation, and specific detection property and very low detection limit for a biomarker mercaptoamino-acid, can be reused after being simply processed, and can be widely applied to the field of health detection.

The present invention provides compounds for disrupting the binding of a matrix metalloprotease (MMP) protein to a substrate protein at an interaction site other than the protease catalytic site. In particular the inventive compounds inhibit the MMP's ability to cleave a substrate protein. In some cases the compound may prevent activation of transforming growth factor beta (TGFβ). The compounds are preferably polypeptide fragments of the hemopexin-like domain of the MMP, but may be mimetics thereof or peptides or mimetics of the portion of the MMP substrate protein to which the MMP interacts.

The invention relates to nucleic acid molecules for use in detecting a target nucleic acid molecule which is a member of a class of nucleic acid molecules and which is characterised by a specific variant region, said nucleic acid molecule comprising (i) a nucleic acid stem region which comprises a nucleic acid interaction site directed to a conserved region of the class of which said target nucleic acid molecule is member, or part thereof and which conserved region is located proximally to a variant region; operate y linked to (ii) a nucleic acid recognition region comprising at least two nucleotides. The nucleic acids are used in arrays and are an efficient means of screening molecules exhibiting a unique nucleotide sequence within a randomly varying population. The invention is useful in monitoring the effectiveness of therapeutic drug therapies and the progression of medical conditions, characterised by the presence of clonal populations of cells, particularly clonal lymphocyte populations.

The invention discloses a method for calculating and identifying protein-RNA interaction sites, which comprises the following steps: a) establishing a protein structure characterization method-amino acid two-dimensional character scoring based on the active ingredient analysis method; b) using the amino acid two-dimensional character scoring for characterizing the structure features of the protein-RNA interaction sites; c) using the genetic algorithm for selecting feature parameters which are closely related to the protein-RNA interaction sites; and d) establishing a protein-RNA interaction site identification model by applying a radial basis kernel support vector machine, and respectively using three methods of self-replacement verification, retaining 1/5 cross-verification and external verification for verifying the predictive capability of the model. The method can be used for prediction and specificity analysis of the protein-RNA interaction sites and is vital for deep understanding of gene expression regulation, protein synthesis and replication, assembly and other processes of a variety of virus.

The invention provides Amylin compatible polypeptide and an application thereof. The amino acid sequence of the compatible polypeptide is LTPHKHHKHLHA. Firstly the compatible polypeptide sequence of specific binding Amylin is obtained through a phage display library and a biopanning technique, then Amylin and compatible polypeptide are subjected to molecular simulation and constant temperature titer thermal analysis, which indicates that the interaction site of the compatible polypeptide and the Amylin comprises that Amylin aggregation forms hot spot sequence of beta-sheet, and the affinity and the combination specificity of the Amylin and the compatible polypeptide are high. The AFM and ThT fluorescence detection experiment indicates that the compatible polypeptide has obvious restraining effects on the process of forming fibers through Amylin aggregation, and certain theoretical basis and test basis are provided for development of Amylin aggregation inhibitors and drugs relevant with non-insulin dependent diabetes.

The invention provides a compound for enhancing space coupling degree of an endothelial cell ion channel complex TRPV4-KCa2.3 and application thereof in resisting hypertension. The compound has the advantages that by finding the structure domain of interaction sites of the endothelial cell ion channel complex TRPV4-KCa2.3, the specific compound which can simultaneously act on the two action sites is prepared; the space coupling degree of the complex TRPV4-KCa2.3 can be enhanced by the compound, and the important meaning is realized for the research and development of hypertension drugs.

The invention discloses a protein interaction site identification method which belongs to the field bioinformatics analysis. The method comprises the steps of acquiring protein chain data, performing preprocessing on the protein chain data, and dividing the preprocessed protein chain data to an interface residue and a non-interface residue; extracting a characteristic from a database, fusing the extracted characteristics for obtaining a data set, processing the unbalance of the data set, then dividing the processed data set into a training set and a testing set, training the XGBoost model by means of the training set, and finally obtaining the protein interaction site by means of the XGBoost model. The protein interaction site identification method aims to overcome a defect of relatively high result analysis difficulty caused by different degrees of false positive and false negative characteristics in predicting the protein interaction site. The protein interaction site identification method can overcome defects above and furthermore can improve identification precision of the protein interaction site.

The invention belongs to the field of molecular virology, and particularly relates to a binding site of interacting a major capsid protein L1 and a secondary capsid protein L2 of a human papilloma virus L1L2. The protein binding site and an area can serve as target sites for preventing HPV infection and diseases such as a cervical cancer caused HPV infection. The invention further relates to an HPV mutant type L1 protein. The invention further relates to a medicament composition and applications of the preparation medicament composition in treating and/preventing and/adjuvantly treating HPV infection and diseases such as a cervical cancer caused by HPV infection.

The invention discloses a preparation method of a tetraethylenepentamine carbon quantum dot/monomer co-bonded silica gel chromatographic packing. The preparation method comprises the following steps:reacting tetraethylenepentamine (TEPA) serving as a precursor substance and a medium with citric acid to prepare a mixture of functionalized carbon quantum dots (TEPACDs) and a TEPA monomer; and carrying out silanization treatment on the functionalized carbon quantum dots TEPACDs, and bonding the silanized functionalized carbon quantum dots TEPACDs to the surface of silica gel to prepare the silica gel chromatographic stationary phase Sil-TEPA/CDs formed by co-bonding of the TEPACDs and the TEPA monomer. Material characterization experiments show that the bonding amount of surface functional groups of the Sil-TEPA/CDs is large, and rich interaction sites can be provided for chromatographic separation of samples. Chromatographic separation experiments show that the hydrophilic chromatographic stationary phase Sil-TEPA/CDs prepared by the invention has good hydrophilic chromatographic selectivity, and has an excellent separation effect on basic nucleoside, amino acids and ginsenoside.

The invention relates to a method for forming two-dimensional polypeptide nanosheets by regulating assembly of polypeptides with organic micromolecules, belonging to the technical field of biological materials. The method comprises the following steps: (1) selecting a molecule self-assembly polypeptide, and selecting an organic micromolecule regulator; (2) thoroughly mixing the polypeptide molecule and the regulator molecule to form a mixed solution; and incubating at 37 DEG C for 7 days. The molecule regulator is introduced on the molecular level to regulate the polypeptides to form a two-dimensional self-assembly sheet structure. The scanning tunnel microtechnique on the molecular level observes that the regulator molecule can regulate the surfactant-like polypeptide assembly structure. The invention provides the interaction site between the regulator molecule and polypeptide on the molecular level, so that people can clearly understand the polypeptide assembly mechanism under the regulation of the regulator molecule.

The invention discloses a method for predicting protein-RNA interaction sites. Multiple kinds of characteristic data of a protein-RNA compound are combined for forming a complicated multidimensional characteristic set. Then an effective characteristic with high weight is selected through a characteristic selecting algorithm. Finally a protein-RNA interaction site is predicted through a machine learning algorithm. Compared with the prior art, the method is advantageous in that more and more effective characteristics are fused; a more advanced algorithm is used; the more effective characteristics are selected; and besides consideration of prediction of the protein-RNA interaction sites which are proved by experiments, more data can be integrated, such as protein-DNA interaction sides. According to the method of the invention, through fusing more effective algorithm and more characteristic data, the protein-RNA interaction sites can be more accurately predicted than previous technology. Furthermore multiple pairs of protein-RNA interaction sites can be predicted in one time in a large scale manner, thereby effectively settling problems of blindness and high cost of a biological experiment method.